MAYZENT®

Hold Company

NOVARTIS

Learn More

Dosage and Administration

TABLET;ORAL

Specification

EQ 0.25MG BASE; EQ 1MG BASE; EQ 2MG BASE

Indication

MAYZENT® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndromes, relapsing remitting disease, and active secondary progressive disease.

Use

Instructions for Use

API

SIPONIMOD

API Structure

We Supply

SIPONIMOD

Note:

null

null

Note:

null

null

Note:

null

Drug Patent

Patent No	Expiration Date
7939519	2028/8/27
8492441	2030/11/30

API Patent

Patent No	Expiration Date
7939519	2028/8/27

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.